Reliance Life Sciences Private Limited — Temozolomide Exporter Profile
Indian Pharmaceutical Exporter · #4 for Temozolomide · $1.7M export value · DGFT Verified
Reliance Life Sciences Private Limited is the #4 Indian exporter of Temozolomide with $1.7M in export value and 100 verified shipments. Reliance Life Sciences Private Limited holds a 7.1% market share in Temozolomide exports across 14 countries. The company exports 14 pharmaceutical products worth $42.3M across 4 therapeutic categories.
Reliance Life Sciences Private Limited — Temozolomide Export Profile: Buyers & Destinations
Where Does Reliance Life Sciences Private Limited Export Temozolomide?
| Country | Value | Shipments | Share |
|---|---|---|---|
| TURKEY | $488.6K | 18 | 31.6% |
| CANADA | $447.4K | 19 | 28.9% |
| VIETNAM, DEMOCRATIC REP. OF | $278.0K | 10 | 18.0% |
| VIETNAM | $110.6K | 4 | 7.1% |
| BELGIUM | $85.6K | 13 | 5.5% |
| UNITED KINGDOM | $32.9K | 4 | 2.1% |
| SINGAPORE | $24.7K | 10 | 1.6% |
| GAUTEMALA | $24.3K | 2 | 1.6% |
| PARAGUAY | $19.6K | 7 | 1.3% |
| SRI LANKA | $15.7K | 2 | 1.0% |
Reliance Life Sciences Private Limited exports Temozolomide to 15 countries. The largest destination is TURKEY accounting for 31.6% of Reliance Life Sciences Private Limited's Temozolomide shipments, followed by CANADA (28.9%) and VIETNAM, DEMOCRATIC REP. OF (18.0%). These destinations reflect Reliance Life Sciences Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Temozolomide from Reliance Life Sciences Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| DEM PHARMACEUTICALS | TURKEY | $401.7K | 15 |
| JAMP PHARMA CORP | CANADA | $305.1K | 12 |
| DELTA IMPORT-EXPORT MEDICAL CO.LTD | VIETNAM, DEMOCRATIC REP. OF | $189.3K | 7 |
| DELTA IMPORT - EXPORT MEDICAL CO., | VIETNAM, DEMOCRATIC REP. OF | $109.5K | 4 |
| JAMP PHARMA CORP, | CANADA | $108.2K | 3 |
| DEM PHARMACEUTICALS DEM ILAC DEM PLAZA INONU MAH | TURKEY | $86.8K | 3 |
| ESSARS NV | BELGIUM | $85.6K | 13 |
| DELTA IMPORT - EXPORT MEDICAL CO. L | VIETNAM, DEMOCRATIC REP. OF | $49.4K | 2 |
| DELTA IMPORT - EXPORT MEDICAL CO | VIETNAM | $40.4K | 1 |
| MAWDSLEY PRE-WHOLESALE | UNITED KINGDOM | $32.9K | 4 |
Reliance Life Sciences Private Limited supplies Temozolomide to 26 buyers globally. The largest buyer is DEM PHARMACEUTICALS (TURKEY), followed by JAMP PHARMA CORP (CANADA) and DELTA IMPORT-EXPORT MEDICAL CO.LTD (VIETNAM, DEMOCRATIC REP. OF). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Temozolomide Export Value and How Much Does Reliance Life Sciences Private Limited Contribute?
India exported $21.7M worth of Temozolomide through 1,261 shipments from 133 suppliers to 90 countries, serving 250 buyers globally. Reliance Life Sciences Private Limited contributes $1.7M to this total, accounting for 7.1% of India's Temozolomide exports. Reliance Life Sciences Private Limited ships Temozolomide to 15 countries through 26 buyers.
What Is the Average Shipment Value for Reliance Life Sciences Private Limited's Temozolomide Exports?
Reliance Life Sciences Private Limited's average Temozolomide shipment value is $16.7K per consignment, based on 100 shipments totaling $1.7M. The largest destination is TURKEY (31.6% of Reliance Life Sciences Private Limited's Temozolomide exports).
How Does Reliance Life Sciences Private Limited Compare to Other Indian Temozolomide Exporters?
Reliance Life Sciences Private Limited ranks #4 among 133 Indian Temozolomide exporters with a 7.1% market share. The top 3 exporters are SUN PHARMACEUTICAL INDUSTRIES LIMITED ($14.7M), JODAS EXPOIM PRIVATE LIMITED ($1.8M), RELIANCE LIFE SCIENCES PRIVATE LIMITED ($1.7M). Reliance Life Sciences Private Limited processed 100 shipments to 14 destination countries.
What Temozolomide Formulations Does Reliance Life Sciences Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| TEMOZOLID 100 MG TEMOZOLOMIDE 100 mg | $100.0K | 2 |
| TEMOZOLOMIDE 100MG (TEMOREL 100MG) (2000 | $79.4K | 2 |
| TEMOZOLID 100MG TEMOZOLOMIDE 100MG | $50.0K | 1 |
| TEMOREL 100MG TEMOREL 100MG (TEMOZOLOMIDE 100MG)NOS | $50.0K | 1 |
| TEMOZOLID 100 MG TEMOZOLOMIDE 100 MGNOS | $50.0K | 1 |
| TEMOZOLOMIDE 100MG (TEMOZOLID 100MG) | $50.0K | 1 |
| TEMOZOLOMIDE 140 MG (1 X 5'S) B. NO.RLTS0124A, MFG DT.MAR-2024 EXP DT.FEB-2026 | $50.0K | 1 |
| TEMOZOLOMIDE 100 MG (1 X 5'S) B. NO.RLTM0424A, MFG DT.MAR-2024 EXP DT.FEB-2026 | $50.0K | 1 |
| TEMOZOLID 100 MG TEMOZOLOMIDE 100 MG | $50.0K | 1 |
| TEMOZOLID 250 MG TEMOZOLOMIDE 250 mg | $46.4K | 2 |
Reliance Life Sciences Private Limited exports 85 distinct Temozolomide formulations including tablets, capsules, syrups, and combination drugs. The top formulation is TEMOZOLID 100 MG TEMOZOLOMIDE 100 mg with 2 shipments worth $100.0K.
Regulatory Requirements: Exporting Temozolomide to Key Markets
What Reliance Life Sciences Private Limited must comply with to export Temozolomide to its top destination countries
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Reliance Life Sciences Private Limited Compare to Nearest Temozolomide Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $14.7M | 311 | 8 | $47.1K |
| 3 | JODAS EXPOIM PRIVATE LIMITED | $1.8M | 35 | 5 | $50.0K |
| 4 | RELIANCE LIFE SCIENCES PRIVATE LIMITED ★ | $1.7M | 100 | 14 | $16.7K |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LTD | $950.0K | 19 | 4 | $50.0K |
| 5 | INTAS PHARMACEUTICALS LIMITED | $825.2K | 49 | 9 | $16.8K |
Reliance Life Sciences Private Limited ranks #4 among 133 Indian Temozolomide exporters. Average shipment value of $16.7K compared to the market average of $163.4K. The closest competitors by value are SUN PHARMACEUTICAL INDUSTRIES LIMITED and JODAS EXPOIM PRIVATE LIMITED.
Which Indian Ports Ship Temozolomide Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 247 | 19.6% |
| SAHAR AIR | 221 | 17.5% |
| NHAVA SHEVA SEA (INNSA1) | 112 | 8.9% |
| DELHI AIR CARGO ACC (INDEL4) | 99 | 7.9% |
| DELHI AIR | 72 | 5.7% |
| JNPT/ NHAVA SHEVA SEA | 53 | 4.2% |
| Bombay Air | 51 | 4.0% |
| HYDERABAD ACC (INHYD4) | 50 | 4.0% |
What Other Advanced Oncology Products Does Reliance Life Sciences Private Limited Export?
Reliance Life Sciences Private Limited also exports these advanced oncology products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Reliance Life Sciences Private Limited's Temozolomide Exports
RLS's export operations are influenced by a complex geopolitical landscape. The ongoing Israel-Iran tensions have disrupted Red Sea shipping routes, leading to increased freight costs and potential delays. The Pharmaceuticals Export Promotion Council of India estimates that the domestic pharma industry could face losses between ₹2,500 crore and ₹5,000 crore due to these disruptions. (medicaldialogues.in) As a significant exporter, RLS must navigate these challenges to maintain its market share and delivery timelines.
Conversely, the U.S.-China trade tensions have opened opportunities for Indian pharmaceutical companies. With the U.S. seeking to diversify its supply chains, Indian exporters like RLS could benefit from increased demand. However, the imposition of broad tariffs by the U.S. administration, with rates reaching as high as 39%, poses a risk to Indian exporters, potentially affecting nearly 55% of the country's outbound shipments to America. (apnews.com) Additionally, the India–EFTA Trade and Economic Partnership Agreement, effective from October 2025, aims to eliminate or reduce tariffs on goods traded between India and EFTA countries, potentially enhancing RLS's access to European markets. (en.wikipedia.org)
Reliance Life Sciences Private Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for RLS's export success. The company must adhere to stringent FDA, WHO, and EU GMP guidelines to ensure product quality and safety. The evolving regulatory landscape, including the EU's falsified medicines directive, necessitates continuous investment in quality assurance and compliance mechanisms. RLS's proactive approach to regulatory compliance, evidenced by its investments in state-of-the-art manufacturing facilities, positions it favorably in the global market.
About Reliance Life Sciences Private Limited
Reliance Life Sciences Private Limited exports 14 products worth $42.3M. Beyond Temozolomide, top products include Immunoglobulin, Lenalidomide, Rituximab, Trastuzumab, Kit. View the complete Reliance Life Sciences Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Temozolomide — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Temozolomide shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Reliance Life Sciences Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 100 individual customs records matching Reliance Life Sciences Private Limited exporting Temozolomide, covering 85 formulations to 15 countries via 26 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 90+ countries, 250+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Temozolomide Export Data from Reliance Life Sciences Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Reliance Life Sciences Private Limited's Temozolomide exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Reliance Life Sciences Private Limited
Full Company Profile →
14 products · $42.3M total trade · 4 categories
Temozolomide Stats
Company Overview
Top Products by Reliance Life Sciences Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Reliance Life Sciences Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Temozolomide. For current shipment-level data, contact TransData Nexus.